Home » Topics » Regulatory » EMA

EMA
RSS

EMA committee recommends approval of baricitinib for RA

Dec. 19, 2016

Novartis' Votubia receives positive opinion in E.U.

Dec. 19, 2016

EMA's CHMP backs approval of canakinumab in periodic fever syndromes

Dec. 19, 2016

Gedeon Richter withdraws European applications for biosimilar pegfilgrastim

Dec. 19, 2016

Minoryx Therapeutics' lead candidate granted orphan drug designation in Europe

Dec. 19, 2016

EMA grants orphan designation to REGN-2477 for fibrodysplasia ossificans progressiva

Dec. 16, 2016

CM-4620 receives EMA orphan designation for acute pancreatitis

Dec. 15, 2016

EMA grants UGT1A1 gene therapy orphan designation for Crigler-Najjar syndrome

Dec. 14, 2016

EMA validates Oxervate MAA for neurotrophic keratitis

Dec. 13, 2016

EMA accepts for review MAA for dupilumab in atopic dermatitis

Dec. 9, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...